Xin Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Xin Yang has a total of 675 co-authors. Here are the top co-authors by number of shared publications:
- Antonis C. Antoniou
Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge , Cambridge CB1 8RN
14 shared publications - Douglas F. Easton
Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge , Cambridge CB1 8RN
14 shared publications - Joe Dennis
Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Cambridge, UK
11 shared publications - Paul David Peter Pharoah
Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, CA, USA
8 shared publications - Goska Leslie
Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
7 shared publications Marc Tischkowitz
Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK
7 shared publications
Latest Publications
- Open Access
Contribution of Risk Factors, Including Polygenic Score, to the Multifactorial Risk Assessment for the Implementation of Personalized Breast Cancer Screening: Insights from the PERSPECTIVE: Integration and Implementation Project
Background/Objectives: Risk-based breast cancer (BC) screening can provide tailored recommendations based on individual risk. We aimed to identify key predictors for BC risk stratification to inform implementation in screening programs. Methods: We estimated 10-year BC risks using BOADICEA v.6 (CanRisk) in 3753 women aged 40–70 with no cancer history from the PERSPECTIVE I&I cohort. The primary endpoint was risk reclassification, assessed as the proportion of women whose assigned 10-year risk category changed when using different risk factor combinations against a full multifactorial model including questionnaire-based risk factors (QRFs), polygenic score (PGS), mammographic density (MD), and pedigree-structured first- and second-degree family history (FH) of breast, ovarian, pancreatic and prostate cancer, including both affected and unaffected relatives. Relative risk thresholds were set as <1.5 (average), 1.5–2.7 (higher-than-average), and ≥2.7 (high), equivalent to the remaining lifetime risk categories of <15%, 15–25% and ≥25% for women aged 30 (the anchor) to age 80. We quantified individual-level reclassification flows by direction and magnitude. Results: Excluding PGS from risk calculations led to the highest overall reclassification. Using only the BC status in first- and second-degree relatives produced comparable risk classification to that of the full FH data that included breast, ovarian, prostate and pancreatic cancer (reclassification = 0.5%). However, collecting only affected relatives led to overestimation of risk. Excluding either PGS, MD or FH resulted in a greater proportion of reclassification among younger women. Adding the PGS to risk factors already collected in provincial screening programs reduced reclassification from 23% to ~13%. Conclusions: PGS, MD, QRFs and FH of BC in affected and unaffected first- and second-degree relatives are key for refining risk stratification. These findings provide real-world evidence on how incorporating different sets of risk factors, both those routinely collected in screening programs and those requiring additional data collection, affect individual-level risk classification amongst a population-based cohort, and how the impacts differ across age groups. While risk classification reflects model-based changes in estimated risk categories rather than direct evidence of mis-screening or clinical outcomes, comparison with the current eligibility criteria used to identify women at higher-than-average risk highlights the potential clinical value of a multifactorial risk assessment approach in ensuring more appropriate screening strategies.
Open AccessContribution of Risk Factors, Including Polygenic Score, to the Multifactorial Risk Assessment for the Implementation of Personalized Breast Cancer Screening: Insights from the PERSPECTIVE: Integration and Implementation Project
Background/Objectives: Risk-based breast cancer (BC) screening can provide tailored recommendations based on individual risk. We aimed to identify key predictors for BC risk stratification to inform implementation in screening programs. Methods: We estimated 10-year BC risks using BOADICEA v.6 (CanRisk) in 3753 women aged 40–70 with no cancer history from the PERSPECTIVE I&I cohort. The primary endpoint was risk reclassification, assessed as the proportion of women whose assigned 10-year risk category changed when using different risk factor combinations against a full multifactorial model including questionnaire-based risk factors (QRFs), polygenic score (PGS), mammographic density (MD), and pedigree-structured first- and second-degree family history (FH) of breast, ovarian, pancreatic and prostate cancer, including both affected and unaffected relatives. Relative risk thresholds were set as <1.5 (average), 1.5–2.7 (higher-than-average), and ≥2.7 (high), equivalent to the remaining lifetime risk categories of <15%, 15–25% and ≥25% for women aged 30 (the anchor) to age 80. We quantified individual-level reclassification flows by direction and magnitude. Results: Excluding PGS from risk calculations led to the highest overall reclassification. Using only the BC status in first- and second-degree relatives produced comparable risk classification to that of the full FH data that included breast, ovarian, prostate and pancreatic cancer (reclassification = 0.5%). However, collecting only affected relatives led to overestimation of risk. Excluding either PGS, MD or FH resulted in a greater proportion of reclassification among younger women. Adding the PGS to risk factors already collected in provincial screening programs reduced reclassification from 23% to ~13%. Conclusions: PGS, MD, QRFs and FH of BC in affected and unaffected first- and second-degree relatives are key for refining risk stratification. These findings provide real-world evidence on how incorporating different sets of risk factors, both those routinely collected in screening programs and those requiring additional data collection, affect individual-level risk classification amongst a population-based cohort, and how the impacts differ across age groups. While risk classification reflects model-based changes in estimated risk categories rather than direct evidence of mis-screening or clinical outcomes, comparison with the current eligibility criteria used to identify women at higher-than-average risk highlights the potential clinical value of a multifactorial risk assessment approach in ensuring more appropriate screening strategies.
- Open Access
- 1 February 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (2) , e2500852
Modeling Individual-Level Uncertainty From Missing Data in Multifactorial Breast Cancer Risk Prediction
PURPOSE: Multifactorial breast cancer (BC) risk prediction models use a range of predictors to estimate an individual's chance of developing BC. Data on risk factors are often incomplete, and point estimates calculated when data are missing can mask considerable uncertainty. Quantifying this uncertainty is critical for effective risk communication. METHODS: We used Monte Carlo simulation methods to estimate the distribution of 10-year BC risk for individuals with missing data, using the BOADICEA multifactorial model as an example. Multivariate imputation by chained equations with large representative reference data sets was used to sample missing covariates. We developed a framework for estimating the uncertainty distribution, uncertainty intervals (UIs), and probability of reclassification, which can be applied to any given individual with missing risk factor data. This was applied to estimating individual-level uncertainty distributions and quantifying the probability of reclassification when groups of risk factors are measured, for a range of example women. RESULTS: Women with limited risk factor data had considerable uncertainty in their estimated BC risk, and 95% UIs spanned all risk categories. This was especially relevant for women classified as moderate-risk, such as those with strong family history or a moderate-risk pathogenic variant. Reclassification probability in this case was as high as 57.5%, with 95% UI of 0.9% to 9.3% for the 10-year risk from age 40 years. Risk certainty improved with additional data collection, particularly genetic information or mammographic density measurement. CONCLUSION: Our results demonstrate that, in some cases, there is considerable probability of reclassification after collecting missing data. Methodology presented here can identify situations where it would be most beneficial to collect additional information, to enable better informed clinical decision making.
- 1 February 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (2) , e2500852
Open AccessModeling Individual-Level Uncertainty From Missing Data in Multifactorial Breast Cancer Risk Prediction
PURPOSE: Multifactorial breast cancer (BC) risk prediction models use a range of predictors to estimate an individual's chance of developing BC. Data on risk factors are often incomplete, and point estimates calculated when data are missing can mask considerable uncertainty. Quantifying this uncertainty is critical for effective risk communication. METHODS: We used Monte Carlo simulation methods to estimate the distribution of 10-year BC risk for individuals with missing data, using the BOADICEA multifactorial model as an example. Multivariate imputation by chained equations with large representative reference data sets was used to sample missing covariates. We developed a framework for estimating the uncertainty distribution, uncertainty intervals (UIs), and probability of reclassification, which can be applied to any given individual with missing risk factor data. This was applied to estimating individual-level uncertainty distributions and quantifying the probability of reclassification when groups of risk factors are measured, for a range of example women. RESULTS: Women with limited risk factor data had considerable uncertainty in their estimated BC risk, and 95% UIs spanned all risk categories. This was especially relevant for women classified as moderate-risk, such as those with strong family history or a moderate-risk pathogenic variant. Reclassification probability in this case was as high as 57.5%, with 95% UI of 0.9% to 9.3% for the 10-year risk from age 40 years. Risk certainty improved with additional data collection, particularly genetic information or mammographic density measurement. CONCLUSION: Our results demonstrate that, in some cases, there is considerable probability of reclassification after collecting missing data. Methodology presented here can identify situations where it would be most beneficial to collect additional information, to enable better informed clinical decision making.
- Open Access
- 1 October 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500203
Incorporating Continuous Mammographic Density Into the BOADICEA Breast Cancer Risk Prediction Model
PURPOSE: Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA v7) predicts future breast cancer (BC) risk using data on cancer family history (FH), genetic markers, questionnaire-based risk factors, and mammographic density (MD) measured using the four-category Breast Imaging Reporting and Data System (BIRADS) classification. However, BIRADS requires manual reading, which is impractical on a large scale and may cause information loss. We extended BOADICEA to incorporate continuous MD measurements, calculated using the automated Volpara and STRATUS tools. METHODS: We used data from the Karolinska Mammography Project for Risk Prediction of Breast Cancer cohort (60,276 participants; 1,167 incident BC). Associations between MD measurements and BC risk were estimated in a randomly selected training subset (two thirds of the data set). Percent MD residuals were calculated after regressing on age at mammography and BMI. Hazard ratios (HRs) were estimated using a Cox proportional hazards model, adjusting for FH and BOADICEA risk factors, and were incorporated into BOADICEA. The remaining one third of the cohort was used to assess the performance of the extended BOADICEA (v7.2) in predicting 5-year risks. RESULTS: The BC HRs per standard deviation of residual STRATUS density were estimated to be 1.48 (95% CI, 1.33 to 1.64) and 1.41 (95% CI, 1.27 to 1.56) for pre- and postmenopausal women, respectively. The corresponding estimates for Volpara density were 1.27 (95% CI, 1.15 to 1.40) and 1.38 (95% CI, 1.25 to 1.54). The extended BOADICEA showed improved discrimination in the testing data set over using BIRADS, with a 1%-4% increase in AUC across different combinations of risk factors. On the basis of 5-year BC risk with MD as the sole input, approximately 11% of the women were reclassified into lower risk categories and 18% into higher risk categories using the extended model. CONCLUSION: Incorporating continuous MD measurements into BOADICEA enhances BC risk stratification and facilitates the use of automated MD measures for risk prediction.
- 1 October 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500203
Open AccessIncorporating Continuous Mammographic Density Into the BOADICEA Breast Cancer Risk Prediction Model
PURPOSE: Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA v7) predicts future breast cancer (BC) risk using data on cancer family history (FH), genetic markers, questionnaire-based risk factors, and mammographic density (MD) measured using the four-category Breast Imaging Reporting and Data System (BIRADS) classification. However, BIRADS requires manual reading, which is impractical on a large scale and may cause information loss. We extended BOADICEA to incorporate continuous MD measurements, calculated using the automated Volpara and STRATUS tools. METHODS: We used data from the Karolinska Mammography Project for Risk Prediction of Breast Cancer cohort (60,276 participants; 1,167 incident BC). Associations between MD measurements and BC risk were estimated in a randomly selected training subset (two thirds of the data set). Percent MD residuals were calculated after regressing on age at mammography and BMI. Hazard ratios (HRs) were estimated using a Cox proportional hazards model, adjusting for FH and BOADICEA risk factors, and were incorporated into BOADICEA. The remaining one third of the cohort was used to assess the performance of the extended BOADICEA (v7.2) in predicting 5-year risks. RESULTS: The BC HRs per standard deviation of residual STRATUS density were estimated to be 1.48 (95% CI, 1.33 to 1.64) and 1.41 (95% CI, 1.27 to 1.56) for pre- and postmenopausal women, respectively. The corresponding estimates for Volpara density were 1.27 (95% CI, 1.15 to 1.40) and 1.38 (95% CI, 1.25 to 1.54). The extended BOADICEA showed improved discrimination in the testing data set over using BIRADS, with a 1%-4% increase in AUC across different combinations of risk factors. On the basis of 5-year BC risk with MD as the sole input, approximately 11% of the women were reclassified into lower risk categories and 18% into higher risk categories using the extended model. CONCLUSION: Incorporating continuous MD measurements into BOADICEA enhances BC risk stratification and facilitates the use of automated MD measures for risk prediction.
- Open Access
- 17 July 2025
- Published by Springer Nature in British Journal of Cancer
- Vol. 133 (6) , 844-855
Adapting the BOADICEA breast and ovarian cancer risk models for the ethnically diverse UK population
Background: BOADICEA is a widely used algorithm for predicting breast and ovarian cancer risks, using a combination of genetic and lifestyle, hormonal and reproductive risk factors. However, it has largely been developed using data from White/European individuals, limiting its applicability to other ethnicities. Here, we updated BOADICEA to provide ethnicity-specific risk estimates. Methods: We utilised data from multiple sources to derive estimates for the distributions and effect sizes of risk factors in major UK ethnic groups (White, Black, South Asian, East Asian, and Mixed), along with ethnicity-specific population cancer incidences. We also developed a method for deriving adjusted polygenic scores for individuals of mixed genetic ancestry. Results: The predicted average absolute risks were smaller in all non-White ethnic groups than in Whites, and the risk distributions were narrower. The proportion of women classified as at moderate or high risk of breast or ovarian cancer, according to national guidelines, was considerably smaller in non-Whites. Discussion: The updated BOADICEA, available in the CanRisk tool (www.canrisk.org), is based on more appropriate estimates for non-White women in the UK. Further validation of the model in prospective studies is required. Considering these findings, risk classification guidelines for non-White women may need to be revised.
- 17 July 2025
- Published by Springer Nature in British Journal of Cancer
- Vol. 133 (6) , 844-855
Open AccessAdapting the BOADICEA breast and ovarian cancer risk models for the ethnically diverse UK population
Background: BOADICEA is a widely used algorithm for predicting breast and ovarian cancer risks, using a combination of genetic and lifestyle, hormonal and reproductive risk factors. However, it has largely been developed using data from White/European individuals, limiting its applicability to other ethnicities. Here, we updated BOADICEA to provide ethnicity-specific risk estimates. Methods: We utilised data from multiple sources to derive estimates for the distributions and effect sizes of risk factors in major UK ethnic groups (White, Black, South Asian, East Asian, and Mixed), along with ethnicity-specific population cancer incidences. We also developed a method for deriving adjusted polygenic scores for individuals of mixed genetic ancestry. Results: The predicted average absolute risks were smaller in all non-White ethnic groups than in Whites, and the risk distributions were narrower. The proportion of women classified as at moderate or high risk of breast or ovarian cancer, according to national guidelines, was considerably smaller in non-Whites. Discussion: The updated BOADICEA, available in the CanRisk tool (www.canrisk.org), is based on more appropriate estimates for non-White women in the UK. Further validation of the model in prospective studies is required. Considering these findings, risk classification guidelines for non-White women may need to be revised.
- Open Access
- 1 June 2025
- Published by BMJ in Journal of Medical Genetics
- Vol. 62 (9)
Associations betweenATMc.7271T>G and cancer risk: analysis of Breast Cancer Association Consortium and UK Biobank data
Previous studies have suggested the missense variant NM_000051.4(ATM):c.7271T>G is associated with a high risk of breast cancer (BC), but the magnitude of the association, and the associations with other cancer types, are unclear. Cancer associations were evaluated using sequence data linked to cancer registration data (348 488 participants, 56 640 cancer cases) from UK Biobank (UKB), and targeted sequence or genome-wide array data (126 428 cases, 115 495 controls) from the Breast Cancer Association Consortium (BCAC). The magnitudes of the association of c.7271T>G with invasive BC were similar using UKB (relative risk (RR): 4.57, 95% CI: 2.25 to 9.30, p=2.7×10−5) and BCAC (OR: 4.11, 2.05 to 8.26, p=6.9×10−5). In UKB, c.7271T>G was associated with increased risks of prostate cancer (4.84, 2.27 to 10.33, p=4.54×10−5), and any other cancer (males 2.79, 1.33 to 5.85, p=0.0066; females 3.15, 1.49 to 6.63, p=0.0026). Estimated cumulative risks of all cancers to age 80 years were 87% in males (prostate cancer 43%) and 84% in females (BC 43%). The estimated RRs are consistent with c.7271T>G being associated with a risk of more than twice that for Ataxia–Telangiectasia Mutated protein-truncating variants, for all cancers. These data justify specific management of c.7271T>G carriers.
- 1 June 2025
- Published by BMJ in Journal of Medical Genetics
- Vol. 62 (9)
Open AccessAssociations betweenATMc.7271T>G and cancer risk: analysis of Breast Cancer Association Consortium and UK Biobank data
Previous studies have suggested the missense variant NM_000051.4(ATM):c.7271T>G is associated with a high risk of breast cancer (BC), but the magnitude of the association, and the associations with other cancer types, are unclear. Cancer associations were evaluated using sequence data linked to cancer registration data (348 488 participants, 56 640 cancer cases) from UK Biobank (UKB), and targeted sequence or genome-wide array data (126 428 cases, 115 495 controls) from the Breast Cancer Association Consortium (BCAC). The magnitudes of the association of c.7271T>G with invasive BC were similar using UKB (relative risk (RR): 4.57, 95% CI: 2.25 to 9.30, p=2.7×10−5) and BCAC (OR: 4.11, 2.05 to 8.26, p=6.9×10−5). In UKB, c.7271T>G was associated with increased risks of prostate cancer (4.84, 2.27 to 10.33, p=4.54×10−5), and any other cancer (males 2.79, 1.33 to 5.85, p=0.0066; females 3.15, 1.49 to 6.63, p=0.0026). Estimated cumulative risks of all cancers to age 80 years were 87% in males (prostate cancer 43%) and 84% in females (BC 43%). The estimated RRs are consistent with c.7271T>G being associated with a risk of more than twice that for Ataxia–Telangiectasia Mutated protein-truncating variants, for all cancers. These data justify specific management of c.7271T>G carriers.
- Open Access
- 12 December 2024
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (5) , 948-958
Evaluating the performance of the Breast and Ovarian Analysis of Disease Incidence Algorithm model in predicting 10-year breast cancer risks in UK Biobank
Background: The Breast and Ovarian Analysis of Disease Incidence Algorithm (BOADICEA) model predicts breast cancer risk using cancer family history, epidemiological, and genetic data. We evaluated its validity in a large prospective cohort. Methods: We assessed model calibration, discrimination and risk classification ability in 217 885 women (6838 incident breast cancers) aged 40-70 years of self-reported White ethnicity with no previous cancer from the UK Biobank. Age-specific risk classification was assessed using relative risk thresholds equivalent to the absolute lifetime risk categories of less than 17%, 17%-30%, and 30% or more, recommended by the National Institute for Health and Care Excellence guidelines. We predicted 10-year risks using BOADICEA v.6 considering cancer family history, questionnaire-based risk factors, a 313–single nucleotide polymorphisms polygenic score, and pathogenic variants. Mammographic density data were not available. Results: The polygenic risk score was the most discriminative risk factor (area under the curve [AUC] = 0.65). Discrimination was highest when considering all risk factors (AUC = 0.66). The model was well calibrated overall (expected-to-observed ratio = 0.99, 95% confidence interval [CI] = 0.97 to 1.02; calibration slope = 0.99, 95% CI = 0.99 to 1.00), and in deciles of predicted risks. Discrimination was similar in women aged younger and older than 50 years. There was some underprediction in women aged younger than 50 years (expected-to-observed ratio = 0.89, 95% CI = 0.84 to 0.94; calibration slope = 0.96, 95% CI = 0.94 to 0.97), which was explained by the higher breast cancer incidence in UK Biobank than the UK population incidence in this age group. The model classified 87.2%, 11.4%, and 1.4% of women in relative risk categories less than 1.6, 1.6-3.1, and at least 3.1, identifying 25.6% of incident breast cancer patients in category relative risk of at least 1.6. Conclusion: BOADICEA, implemented in CanRisk (www.canrisk.org), provides valid 10-year breast cancer risk, which can facilitate risk-stratified screening and personalized breast cancer risk management.
- 12 December 2024
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (5) , 948-958
Open AccessEvaluating the performance of the Breast and Ovarian Analysis of Disease Incidence Algorithm model in predicting 10-year breast cancer risks in UK Biobank
Background: The Breast and Ovarian Analysis of Disease Incidence Algorithm (BOADICEA) model predicts breast cancer risk using cancer family history, epidemiological, and genetic data. We evaluated its validity in a large prospective cohort. Methods: We assessed model calibration, discrimination and risk classification ability in 217 885 women (6838 incident breast cancers) aged 40-70 years of self-reported White ethnicity with no previous cancer from the UK Biobank. Age-specific risk classification was assessed using relative risk thresholds equivalent to the absolute lifetime risk categories of less than 17%, 17%-30%, and 30% or more, recommended by the National Institute for Health and Care Excellence guidelines. We predicted 10-year risks using BOADICEA v.6 considering cancer family history, questionnaire-based risk factors, a 313–single nucleotide polymorphisms polygenic score, and pathogenic variants. Mammographic density data were not available. Results: The polygenic risk score was the most discriminative risk factor (area under the curve [AUC] = 0.65). Discrimination was highest when considering all risk factors (AUC = 0.66). The model was well calibrated overall (expected-to-observed ratio = 0.99, 95% confidence interval [CI] = 0.97 to 1.02; calibration slope = 0.99, 95% CI = 0.99 to 1.00), and in deciles of predicted risks. Discrimination was similar in women aged younger and older than 50 years. There was some underprediction in women aged younger than 50 years (expected-to-observed ratio = 0.89, 95% CI = 0.84 to 0.94; calibration slope = 0.96, 95% CI = 0.94 to 0.97), which was explained by the higher breast cancer incidence in UK Biobank than the UK population incidence in this age group. The model classified 87.2%, 11.4%, and 1.4% of women in relative risk categories less than 1.6, 1.6-3.1, and at least 3.1, identifying 25.6% of incident breast cancer patients in category relative risk of at least 1.6. Conclusion: BOADICEA, implemented in CanRisk (www.canrisk.org), provides valid 10-year breast cancer risk, which can facilitate risk-stratified screening and personalized breast cancer risk management.
- Open Access
The contribution of coding variants to the heritability of multiple cancer types using UK Biobank whole-exome sequencing data
Genome-wide association studies have been highly successful at identifying common variants associated with cancer, however, they do not explain all the inherited risk of cancer. Family-based studies, targeted sequencing and, more recently, exome-wide association studies have identified rare coding variants in some genes associated with cancer risk, but the overall contribution of these variants to the heritability of cancer is less clear. Here we describe a method to estimate the genome-wide contribution of rare coding variants to heritability that fits models to the burden effect sizes using an empirical Bayesian approach. We apply this method to the burden of protein-truncating variants in over 15,000 genes for 11 cancers in UK Biobank, using whole-exome sequencing data on over 400,000 individuals. We extend the method to consider the overlap of genes contributing to pairs of cancers. We found ovarian cancer to have the greatest proportion of heritability attributable to protein-truncating variants in genes (46%). The joint cancer models highlight significant clustering of cancer types, including a near complete overlap in susceptibility genes for breast, ovarian, prostate and pancreatic cancer. Our results provide insights into the contribution of rare coding variants to the heritability of cancer and identify additional genes with strong evidence of susceptibility to multiple cancer types.
Open AccessThe contribution of coding variants to the heritability of multiple cancer types using UK Biobank whole-exome sequencing data
Genome-wide association studies have been highly successful at identifying common variants associated with cancer, however, they do not explain all the inherited risk of cancer. Family-based studies, targeted sequencing and, more recently, exome-wide association studies have identified rare coding variants in some genes associated with cancer risk, but the overall contribution of these variants to the heritability of cancer is less clear. Here we describe a method to estimate the genome-wide contribution of rare coding variants to heritability that fits models to the burden effect sizes using an empirical Bayesian approach. We apply this method to the burden of protein-truncating variants in over 15,000 genes for 11 cancers in UK Biobank, using whole-exome sequencing data on over 400,000 individuals. We extend the method to consider the overlap of genes contributing to pairs of cancers. We found ovarian cancer to have the greatest proportion of heritability attributable to protein-truncating variants in genes (46%). The joint cancer models highlight significant clustering of cancer types, including a near complete overlap in susceptibility genes for breast, ovarian, prostate and pancreatic cancer. Our results provide insights into the contribution of rare coding variants to the heritability of cancer and identify additional genes with strong evidence of susceptibility to multiple cancer types.
- Open Access
- 18 September 2024
- Published by Springer Nature in British Journal of Cancer
- Vol. 131 (9) , 1473-1479
Validation of the BOADICEA model for epithelial tubo-ovarian cancer risk prediction in UK Biobank
Background: The clinical validity of the multifactorial BOADICEA model for epithelial tubo-ovarian cancer (EOC) risk prediction has not been assessed in a large sample size or over a longer term. Methods: We evaluated the model discrimination and calibration in the UK Biobank cohort comprising 199,429 women (733 incident EOCs) of European ancestry without previous cancer history. We predicted 10-year EOC risk incorporating data on questionnaire-based risk factors (QRFs), family history, a 36-SNP polygenic risk score and pathogenic variants (PV) in six EOC susceptibility genes (BRCA1, BRCA2, RAD51C, RAD51D, BRIP1 and PALB2). Results: Discriminative ability was maximised under the multifactorial model that included all risk factors (AUC = 0.68, 95% CI: 0.66–0.70). This model was well calibrated in deciles of predicted risk with calibration slope=0.99 (95% CI: 0.98–1.01). Discriminative ability was similar in women younger or older than 60 years. The AUC was higher when analyses were restricted to PV carriers (0.76, 95% CI: 0.69–0.82). Using relative risk (RR) thresholds, the full model classified 97.7%, 1.7%, 0.4% and 0.2% women in the RR < 2.0, 2.0 ≤ RR < 2.9, 2.9 ≤ RR < 6.0 and RR ≥ 6.0 categories, respectively, identifying 9.1 of incident EOC among those with RR ≥ 2.0. Discussion: BOADICEA, implemented in CanRisk (www.canrisk.org), provides valid 10-year EOC risks and can facilitate clinical decision-making in EOC risk management.
- 18 September 2024
- Published by Springer Nature in British Journal of Cancer
- Vol. 131 (9) , 1473-1479
Open AccessValidation of the BOADICEA model for epithelial tubo-ovarian cancer risk prediction in UK Biobank
Background: The clinical validity of the multifactorial BOADICEA model for epithelial tubo-ovarian cancer (EOC) risk prediction has not been assessed in a large sample size or over a longer term. Methods: We evaluated the model discrimination and calibration in the UK Biobank cohort comprising 199,429 women (733 incident EOCs) of European ancestry without previous cancer history. We predicted 10-year EOC risk incorporating data on questionnaire-based risk factors (QRFs), family history, a 36-SNP polygenic risk score and pathogenic variants (PV) in six EOC susceptibility genes (BRCA1, BRCA2, RAD51C, RAD51D, BRIP1 and PALB2). Results: Discriminative ability was maximised under the multifactorial model that included all risk factors (AUC = 0.68, 95% CI: 0.66–0.70). This model was well calibrated in deciles of predicted risk with calibration slope=0.99 (95% CI: 0.98–1.01). Discriminative ability was similar in women younger or older than 60 years. The AUC was higher when analyses were restricted to PV carriers (0.76, 95% CI: 0.69–0.82). Using relative risk (RR) thresholds, the full model classified 97.7%, 1.7%, 0.4% and 0.2% women in the RR < 2.0, 2.0 ≤ RR < 2.9, 2.9 ≤ RR < 6.0 and RR ≥ 6.0 categories, respectively, identifying 9.1 of incident EOC among those with RR ≥ 2.0. Discussion: BOADICEA, implemented in CanRisk (www.canrisk.org), provides valid 10-year EOC risks and can facilitate clinical decision-making in EOC risk management.
- Open Access
- 29 August 2024
- Published by BMJ in Journal of Medical Genetics
- Vol. 61 (11) , 1016-1022
Protein-truncating and rare missense variants in ATM and CHEK2 and associations with cancer in UK Biobank whole-exome sequence data
Background: Deleterious germline variants in ATM and CHEK2 have been associated with a moderately increased risk of breast cancer. Risks for other cancers remain unclear. Methods: Cancer associations for coding variants in ATM and CHEK2 were evaluated using whole-exome sequence data from UK Biobank linked to cancer registration data (348 488 participants), and analysed both as a retrospective case-control and a prospective cohort study. Odds ratios, hazard ratios, and combined relative risks (RRs) were estimated by cancer type and gene. Separate analyses were performed for protein-truncating variants (PTVs) and rare missense variants (rMSVs; allele frequency ATM were associated with increased risks of nine cancers at pCHEK2 were associated with three cancers at pATM and CHEK2 are associated with a wide range of cancers, with the highest RR for pancreatic cancer in ATM PTV carriers. These findings can inform genetic counselling of carriers.
- 29 August 2024
- Published by BMJ in Journal of Medical Genetics
- Vol. 61 (11) , 1016-1022
Open AccessProtein-truncating and rare missense variants in ATM and CHEK2 and associations with cancer in UK Biobank whole-exome sequence data
Background: Deleterious germline variants in ATM and CHEK2 have been associated with a moderately increased risk of breast cancer. Risks for other cancers remain unclear. Methods: Cancer associations for coding variants in ATM and CHEK2 were evaluated using whole-exome sequence data from UK Biobank linked to cancer registration data (348 488 participants), and analysed both as a retrospective case-control and a prospective cohort study. Odds ratios, hazard ratios, and combined relative risks (RRs) were estimated by cancer type and gene. Separate analyses were performed for protein-truncating variants (PTVs) and rare missense variants (rMSVs; allele frequency ATM were associated with increased risks of nine cancers at pCHEK2 were associated with three cancers at pATM and CHEK2 are associated with a wide range of cancers, with the highest RR for pancreatic cancer in ATM PTV carriers. These findings can inform genetic counselling of carriers.
- Open Access
Protein-truncating and rare missense variants in ATM and CHEK2 and associations with cancer in UK Biobank whole-exome sequenced data
Summary: Background: Deleterious germline variants in ATM and CHEK2 have been associated with a moderately increased risk of breast cancer. Risks for other cancers remain unclear, and require further investigation. Methods: Cancer associations for coding variants in ATM and CHEK2 were evaluated using whole-exome sequenced data from UK Biobank linked to cancer registration data (348,488 participants), and analysed both as a retrospective case-control and a prospective cohort study. Odds ratios, hazard ratios, and combined relative risks (RRs) were estimated by cancer type and gene. Separate analyses were performed for protein-truncating variants (PTVs) and rare missense variants (rMSVs; allele frequency ATM were associated with increased risks of nine cancers at pCHEK2 were associated with three cancers at pATM and CHEK2 are associated with a wide range of cancers, with the highest RR for pancreatic cancer in ATM PTV carriers. These findings can inform genetic counselling of carriers. WHAT IS ALREADY KNOWN ON THIS TOPIC: While previous research shows there is evidence for association between variants in ATM or CHEK2 and multiple cancer types in individual smaller studies, the associations have not been consistently evaluated across all cancer types and, with the exception of breast cancer, the strengths of association are unclear. WHAT THIS STUDY ADDS: We examined data from a large cohort study to derive relative and absolute risks for all cancer types for carriers of PTVs and rMSVs in CHEK2 and ATM . ATM PTVs were associated with significantly increased risk for 11 of 23 sites examined (nine at pCHEK2 PTVs, statistically significant risks were observed for seven of the 21 sites examined (one at pATM and CHEK2 are included on many cancer gene panels used in family cancer clinics, and the risk estimates from these analyses can inform genetic counselling for carriers. The estimated absolute risks for pancreatic cancer in ATM PTV carriers (11% in males and 8% in females by age 85) are notably higher than for other major pancreatic susceptibility genes including BRCA2, CDK2NA, and PALB2. Our findings can also inform NICE guidelines for pancreatic cancer, which do not currently include ATM .
Open AccessProtein-truncating and rare missense variants in ATM and CHEK2 and associations with cancer in UK Biobank whole-exome sequenced data
Summary: Background: Deleterious germline variants in ATM and CHEK2 have been associated with a moderately increased risk of breast cancer. Risks for other cancers remain unclear, and require further investigation. Methods: Cancer associations for coding variants in ATM and CHEK2 were evaluated using whole-exome sequenced data from UK Biobank linked to cancer registration data (348,488 participants), and analysed both as a retrospective case-control and a prospective cohort study. Odds ratios, hazard ratios, and combined relative risks (RRs) were estimated by cancer type and gene. Separate analyses were performed for protein-truncating variants (PTVs) and rare missense variants (rMSVs; allele frequency ATM were associated with increased risks of nine cancers at pCHEK2 were associated with three cancers at pATM and CHEK2 are associated with a wide range of cancers, with the highest RR for pancreatic cancer in ATM PTV carriers. These findings can inform genetic counselling of carriers. WHAT IS ALREADY KNOWN ON THIS TOPIC: While previous research shows there is evidence for association between variants in ATM or CHEK2 and multiple cancer types in individual smaller studies, the associations have not been consistently evaluated across all cancer types and, with the exception of breast cancer, the strengths of association are unclear. WHAT THIS STUDY ADDS: We examined data from a large cohort study to derive relative and absolute risks for all cancer types for carriers of PTVs and rMSVs in CHEK2 and ATM . ATM PTVs were associated with significantly increased risk for 11 of 23 sites examined (nine at pCHEK2 PTVs, statistically significant risks were observed for seven of the 21 sites examined (one at pATM and CHEK2 are included on many cancer gene panels used in family cancer clinics, and the risk estimates from these analyses can inform genetic counselling for carriers. The estimated absolute risks for pancreatic cancer in ATM PTV carriers (11% in males and 8% in females by age 85) are notably higher than for other major pancreatic susceptibility genes including BRCA2, CDK2NA, and PALB2. Our findings can also inform NICE guidelines for pancreatic cancer, which do not currently include ATM .